ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 275 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 2.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $251,000 | +796.4% | 15,097 | +26.9% | 0.01% | +700.0% |
| Q2 2021 | $28,000 | -86.4% | 11,900 | -95.2% | 0.00% | -90.9% |
| Q1 2021 | $206,000 | +261.4% | 246,200 | +1779.4% | 0.01% | +266.7% |
| Q4 2019 | $57,000 | +111.1% | 13,100 | +1.6% | 0.00% | +50.0% |
| Q1 2019 | $27,000 | +440.0% | 12,900 | -35.5% | 0.00% | – |
| Q4 2018 | $5,000 | -72.2% | 20,000 | +60.0% | 0.00% | -100.0% |
| Q3 2018 | $18,000 | -98.6% | 12,500 | -87.1% | 0.00% | -98.4% |
| Q2 2018 | $1,266,000 | +2045.8% | 96,537 | +248.5% | 0.06% | +2000.0% |
| Q1 2017 | $59,000 | -37.2% | 27,700 | -95.0% | 0.00% | -25.0% |
| Q4 2016 | $94,000 | +4600.0% | 556,300 | +5463.0% | 0.00% | – |
| Q3 2016 | $2,000 | -92.0% | 10,000 | -38.7% | 0.00% | -100.0% |
| Q2 2016 | $25,000 | -98.8% | 16,300 | -97.3% | 0.00% | -99.3% |
| Q1 2016 | $2,095,000 | +14864.3% | 612,530 | +5519.5% | 0.15% | +15200.0% |
| Q4 2015 | $14,000 | -97.7% | 10,900 | -54.9% | 0.00% | -94.7% |
| Q4 2013 | $604,000 | -32.9% | 24,155 | -26.3% | 0.02% | -34.5% |
| Q3 2013 | $900,000 | – | 32,765 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |